MX390755B - Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento. - Google Patents

Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.

Info

Publication number
MX390755B
MX390755B MX2019015676A MX2019015676A MX390755B MX 390755 B MX390755 B MX 390755B MX 2019015676 A MX2019015676 A MX 2019015676A MX 2019015676 A MX2019015676 A MX 2019015676A MX 390755 B MX390755 B MX 390755B
Authority
MX
Mexico
Prior art keywords
iii
manufacture
spiramycin
tumors
isovaleril
Prior art date
Application number
MX2019015676A
Other languages
English (en)
Other versions
MX2019015676A (es
Inventor
Enhong Jiang
Jianlu Dai
Weiqing He
Xiaofeng Zhao
Xunlei Jiang
Yang Jiang
Original Assignee
Shenyang Fuyang Pharmaceutical Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenyang Fuyang Pharmaceutical Tech Co Ltd filed Critical Shenyang Fuyang Pharmaceutical Tech Co Ltd
Publication of MX2019015676A publication Critical patent/MX2019015676A/es
Publication of MX390755B publication Critical patent/MX390755B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describe un medicamento que comprende isovaleril espiramicina I, II y/o III, y el uso de isovaleril espiramicina I, II y/o III en la fabricación de medicamentos para tratar y/o prevenir tumores y el medicamento.
MX2019015676A 2017-07-04 2018-07-04 Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento. MX390755B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710537958 2017-07-04
CN201711450300 2017-12-27
CN201711497546 2017-12-27
CN201711450396 2017-12-27
PCT/CN2018/094504 WO2019007368A1 (zh) 2017-07-04 2018-07-04 异戊酰螺旋霉素i、ii和/或iii在制备治疗和/或预防肿瘤药物方面的应用和药物

Publications (2)

Publication Number Publication Date
MX2019015676A MX2019015676A (es) 2022-03-17
MX390755B true MX390755B (es) 2025-03-21

Family

ID=64950608

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015676A MX390755B (es) 2017-07-04 2018-07-04 Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.

Country Status (12)

Country Link
US (1) US20200163984A1 (es)
EP (1) EP3639829B1 (es)
JP (1) JP7060631B2 (es)
KR (1) KR102375444B1 (es)
CN (1) CN110869027B (es)
AU (1) AU2018298187A1 (es)
CA (1) CA3068921A1 (es)
DK (1) DK3639829T3 (es)
ES (1) ES2912734T3 (es)
MX (1) MX390755B (es)
RU (1) RU2766176C2 (es)
WO (1) WO2019007368A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7127136B2 (ja) * 2018-01-19 2022-08-29 沈陽福洋医薬科技有限公司 ｍＴＯＲ阻害剤、薬物組成物及びその応用
CA3088823A1 (en) 2018-01-19 2019-07-25 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Use of carrimycin or active ingredients thereof
CN111939168B (zh) * 2019-05-16 2023-02-03 沈阳福洋医药科技有限公司 一种用于预防、缓解和/或治疗纤维化的药物、组合产品及其应用
US11351185B2 (en) 2020-03-11 2022-06-07 Asclea Corporation Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis
CN113577086B (zh) * 2020-04-30 2023-05-02 沈阳福洋医药科技有限公司 异戊酰螺旋霉素类化合物或其组合物在制备治疗免疫失调的药物中的应用
CN113372397A (zh) * 2021-06-22 2021-09-10 天方药业有限公司 一种己二酸螺旋霉素的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1540397A (en) * 1976-12-08 1979-02-14 May & Baker Ltd Spiramycin esters
CA2127578A1 (en) * 1993-07-08 1995-01-09 Keiichi Ajito 16-membered macrolide derivatives and process for producing the same
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
JP2009539970A (ja) 2006-06-12 2009-11-19 ラモット アット テル−アビブ ユニバーシティー リミテッド 癌の治療方法
CN101362784A (zh) 2008-10-06 2009-02-11 山东大学 埃博霉素苷类化合物和以其为活性成分的组合物及其应用
CN101785778A (zh) * 2010-03-09 2010-07-28 沈阳同联集团有限公司 异戊酰螺旋霉素i的分离制备及其应用
CN101785779B (zh) 2010-03-09 2014-03-05 沈阳同联集团有限公司 异戊酰螺旋霉素ii的分离制备
CN101773510B (zh) 2010-03-09 2013-06-05 沈阳同联集团有限公司 异戊酰螺旋霉素iii的分离制备
EP2578596B1 (en) * 2010-05-25 2017-04-19 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof
CN102229634B (zh) * 2010-05-25 2014-05-28 沈阳同联集团有限公司 左旋异戊酰螺旋霉素i、其制剂、制备方法及应用
PT3210990T (pt) * 2010-05-25 2020-04-01 Shenyang Fuyang Pharmaceutical Tech Co Ltd Levoisovalerilespiramicina iii e as suas preparações, processos para a sua preparação e as suas utilizações
EP3607952B1 (en) * 2017-04-06 2022-07-06 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Use of carrimycin or pharmaceutically acceptable salt thereof for manufacture of medicament for treatment and/or prevention of tumors

Also Published As

Publication number Publication date
CN110869027B (zh) 2023-09-08
KR102375444B1 (ko) 2022-03-17
WO2019007368A1 (zh) 2019-01-10
ES2912734T3 (es) 2022-05-27
US20200163984A1 (en) 2020-05-28
EP3639829B1 (en) 2022-02-09
CN110869027A (zh) 2020-03-06
CA3068921A1 (en) 2019-01-10
RU2020102713A3 (es) 2021-08-04
RU2020102713A (ru) 2021-08-04
RU2766176C2 (ru) 2022-02-08
DK3639829T3 (da) 2022-05-16
KR20200024280A (ko) 2020-03-06
EP3639829A1 (en) 2020-04-22
JP7060631B2 (ja) 2022-04-26
MX2019015676A (es) 2022-03-17
AU2018298187A1 (en) 2020-02-06
EP3639829A4 (en) 2020-06-24
JP2020528047A (ja) 2020-09-17

Similar Documents

Publication Publication Date Title
MX390755B (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
CO2019008487A2 (es) Compuesto de quinazolina
HRP20260108T1 (hr) Kombinirana terapija koja uključuje inhibitor kras-g12c i jedan ili više dodatnih farmaceutski aktivnih sastojaka za liječenje raka
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
CR20190252A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MX378273B (es) Compuestos activos hacia bromodominios.
MX384403B (es) Terapia de combinación para el tratamiento del cáncer.
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
MX392470B (es) Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
HK1223304A1 (zh) 包含二甲双胍和二氢槲皮素的药物组合及其用於治疗癌症的用途
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
BR112018002530A2 (pt) combinações e usos e tratamentos destas
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
MX2020010938A (es) Medicamento para prevenir y/o tratar el dolor y/o la fiebre, producto compuesto y uso del mismo.